Fresh analysis suggests that patients who discontinue popular weight-loss injections like Wegovy and Mounjaro can put back on reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.
Research printed in a major medical journal demonstrates that while obese people frequently drop about a fifth of their body weight while on the medication, the mass returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such drugs need to be informed of the potential of fast weight regain when the therapy ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a return to starting weight within about one and a half years.
Weighing Therapies
The research, which looked at dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through diet and exercise typically experience a less rapid weight regain—approximately 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Doctors propose the mode of action of the jabs accounts for the amplified regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to produce less of its endogenous hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making overeating much more probable."
An Ongoing Disease?
The NHS suggest the jabs for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals argue that, due to the significant potential of relapse, the treatment might need to be life-long.
This perspective is reinforced by drug manufacturers, who say that the findings "highlight the chronic nature of excess weight," akin to managing conditions like high blood pressure.
Patient Accounts
Users who have discontinued the medication explain a intense resurgence of cravings.
"I experienced something flipping and you're instantly starving," recalled a patient.
The struggle is worsened if patients have not developed sustainable lifestyle or habit modifications during therapy.
Growing Use
Figures indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Adoption is more common among women compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while these medications are powerful agents for shedding pounds, they are not a permanent fix and lasting health benefits hinges on combined behavioural management.
